carboplatin + pemetrexed + toripalimab

This is a combination regimen consisting of three agents: carboplatin, pemetrexed, and toripalimab. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. Pemetrexed is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, thereby blocking DNA replication and cell division. Toripalimab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. This combination has been investigated primarily for advanced non-small cell lung cancer (NSCLC), particularly in patients with EGFR-mutant NSCLC who have progressed after first-line EGFR tyrosine kinase inhibitors but do not harbor the T790M mutation[2][5][6]. The regimen typically involves induction cycles of all three drugs followed by maintenance therapy with pemetrexed and toripalimab[2][6].

Brand names

None known for the combinationTuoyi

Other names

None known for the combination